Primary Biliary Cirrhosis (Primary Biliary Cholangitis) - Drug Pipeline Landscape, 2022
Description
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) - Drug Pipeline Landscape, 2022
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Researcher experts consider it as an autoimmune disease in which the body turns against its own cells and the exact cause is unknown. Researchers believe this autoimmune response may be triggered by environmental and genetic factors.
Primary Biliary Cirrhosis symptoms included dry eyes and mouth, spleen swelling, joint pain, buildup of fluid in the abdomen, jaundice, fatigue and itchy skin.
Blood tests including liver test, antibody test and cholesterol test may be used to diagnose primary biliary cirrhosis. Imaging tests looking at the liver and bile ducts may include fibroscan, ultrasound, MRCP and magnetic resonance elastopraphy.
Treatment of PBC include treating the disease with medications like ursodeoxycholic acid, obeticholic acid symptoms, fibrates and budesonide. Treating the symptoms like fatigue dry eyes and mouth may also alleviate the disease condition.
Report Highlights
Global Insight Service's, Primary Biliary Cirrhosis (Primary Biliary Cholangitis) - Drug Pipeline Landscape, 2022 report provides an overview of the Primary Biliary Cirrhosis pipeline drugs. This report covers detailed insights on Primary Biliary Cirrhosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Primary Biliary Cirrhosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Researcher experts consider it as an autoimmune disease in which the body turns against its own cells and the exact cause is unknown. Researchers believe this autoimmune response may be triggered by environmental and genetic factors.
Primary Biliary Cirrhosis symptoms included dry eyes and mouth, spleen swelling, joint pain, buildup of fluid in the abdomen, jaundice, fatigue and itchy skin.
Blood tests including liver test, antibody test and cholesterol test may be used to diagnose primary biliary cirrhosis. Imaging tests looking at the liver and bile ducts may include fibroscan, ultrasound, MRCP and magnetic resonance elastopraphy.
Treatment of PBC include treating the disease with medications like ursodeoxycholic acid, obeticholic acid symptoms, fibrates and budesonide. Treating the symptoms like fatigue dry eyes and mouth may also alleviate the disease condition.
Report Highlights
Global Insight Service's, Primary Biliary Cirrhosis (Primary Biliary Cholangitis) - Drug Pipeline Landscape, 2022 report provides an overview of the Primary Biliary Cirrhosis pipeline drugs. This report covers detailed insights on Primary Biliary Cirrhosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Primary Biliary Cirrhosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
- Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
- Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
- Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
- Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
89 Pages
- 1. Introduction
- 1.1 Primary Biliary Cirrhosis – Pipeline Drugs, 2022-Coverage
- 2. Disease Overview – Primary Biliary Cirrhosis
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Primary Biliary Cirrhosis – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2022
- 3.3 Products under Development by Companies, 2022
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 Elafibranor
- 5.1.2 Linerixibat
- 5.1.3 Obeticholic Acid
- 5.1.4 Saroglitazar
- 5.1.5 Seladelpar
- 5.1.6 Setanaxib
- 5.2 Clinical Stage Drugs-Phase II
- 5.2.1 ASC42
- 5.2.2 Bezafibrate
- 5.2.3 CNP-104
- 5.2.4 CR845
- 5.2.5 Emtricitabine
- 5.2.6 Golexanolone
- 5.2.7 HTD1801 (BUDCA)
- 5.2.8 RhuDex
- 5.2.9 Volixibat
- 5.3 Clinical Stage Drugs-Phase I
- 5.3.1 [14C]-A4250
- 5.3.2 EP547
- 5.3.3 FM101
- 5.3.4 Norucholic acid
- 5.3.5 OP-724
- 5.3.6 Pemafibrate
- 5.4 Early Stage Drugs-Preclinical
- 5.4.1 Drug for PBC
- 5.4.2 LAPS triple agonist
- 5.4.3 PDC-E2
- 5.4.4 TQA3526
- 5.5 Early Stage Drugs-Discovery
- 5.5.1 RNA Actuator therapeutic
- 5.5.2 PVT-201
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Albireo
- 9.2 Calliditas Therapeutics AB
- 9.3 CAMP4 Therapeutics Corp
- 9.4 Cara Therapeutics, Inc.
- 9.5 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- 9.6 COUR Pharmaceutical Development Company, Inc.
- 9.7 CymaBay Therapeutics, Inc.
- 9.8 Dr. Falk Pharma GmbH
- 9.9 Escient Pharmaceuticals, Inc
- 9.10 Future Medicine Co Ltd
- 9.11 Gannex Pharma Co., Ltd.
- 9.12 Genfit
- 9.13 GentiBio Inc
- 9.14 GlaxoSmithKline
- 9.15 Hanmi Pharmaceuticals Co Ltd
- 9.16 HighTide Biopharma Pty Ltd
- 9.17 Intercept Pharmaceuticals
- 9.18 Kowa Co Ltd
- 9.19 Merck Sharp & Dohme LLC
- 9.20 Mirum Pharmaceuticals, Inc.
- 9.21 Nanjing Chia-tai Tianqing Pharmaceutical
- 9.22 Ohara Pharmaceutical Co., Ltd
- 9.23 Parvus Therapeutics Inc
- 9.24 Selecta Biosciences Inc
- 9.25 Umecrine Cognition AB
- 9.26 Zydus Therapeutics Inc.
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2.1 Clinical Trial Details – Elafibranor /Genfit
- Table 2.2 Clinical Trial Details – Linerixibat/GlaxoSmithKline
- Table 2.3 Clinical Trial Details – Obeticholic Acid /Nanjing Chia-tai Tianqing Pharmaceutical
- Table 2.4 Clinical Trial Details – Saroglitazar /Zydus Therapeutics Inc.
- Table 2.5 Clinical Trial Details – Seladelpar /CymaBay Therapeutics, Inc.
- Table 2.6 Clinical Trial Details – Setanaxib/Calliditas Therapeutics AB
- Table 2.7 Clinical Trial Details – ASC42 /Gannex Pharma Co., Ltd.
- Table 2.8 Clinical Trial Details – Bezafibrate /Intercept Pharmaceuticals
- Table 2.9 Clinical Trial Details – CNP-104/COUR Pharmaceutical Development Company, Inc.
- Table 2.10 Clinical Trial Details – CR845/Cara Therapeutics, Inc.
- Table 2.11 Clinical Trial Details – Emtricitabine/Merck Sharp & Dohme LLC
- Table 2.12 Clinical Trial Details – Golexanolone/Umecrine Cognition AB
- Table 2.13 Clinical Trial Details – HTD1801 (BUDCA)/HighTide Biopharma Pty Ltd
- Table 2.14 Clinical Trial Details – RhuDex/Dr. Falk Pharma GmbH
- Table 2.15 Clinical Trial Details – Volixibat/Mirum Pharmaceuticals, Inc.
- Table 2.16 Clinical Trial Details – [14C]-A4250 /Albireo
- Table 2.17 Clinical Trial Details – EP547/Escient Pharmaceuticals, Inc
- Table 2.18 Clinical Trial Details – Norucholic acid/Dr. Falk Pharma GmbH
- Table 2.19 Clinical Trial Details – OP-724/Ohara Pharmaceutical Co., Ltd
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- Figure 1. 1 Number of Products under Development for Primary Biliary Cirrhosis, 2022
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Primary Biliary Cirrhosis, 2022
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Primary Biliary Cirrhosis, 2022
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Primary Biliary Cirrhosis, 2022
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Primary Biliary Cirrhosis, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
